Conclusions
1 evidence topic · 3 sources
Summary
Imsidolimab has randomized placebo-controlled evidence for acute-flare treatment, while the reported randomized maintenance comparison comprises 16 initial responders. The regulatory update included in this report describes the BLA as under FDA review with a target action date of December 12, 2026. The trial regimens are investigational rather than approved prescribing instructions.